Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
URL-G03
- Development stage
- Unknown
- Lead developer
- United Research Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
URL-G03 is a small molecule therapeutic developed by United Research Laboratories for the treatment of anxiety. According to the company's product pipeline, the drug has received regulatory approval and is part of their commercialized portfolio. As a small molecule indicated for anxiety, it is designed to modulate central nervous system pathways associated with anxiety disorders, although the specific chemical identity and molecular target (such as GABAergic or serotonergic receptors) have not been publicly specified under this particular asset code. The drug represents a commercial-stage asset within the developer's neuropsychiatry offerings.
Beyond the preview
Go deeper on URL-G03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on URL-G03.